Close Lucintel Chat
Didn't Find What You're Looking for?
Call us at +1972 636 5056 or write at helpdesk@Lucintel.com
Ask an Expert Provide Custom Requirements Download Sample Report Search Available Reports
  • helpdesk@Lucintel.com
  • |
  • Call Lucintel +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |
'
...

The Impact of COVID-19 is included in Nuclear Medicine/Radiopharmaceutical Market. Buy it today to get an advantage.

Request the impact of COVID-19 on your product or industry


The future of the nuclear medicine/radiopharmaceutical market looks promising with opportunities in the hospitals, diagnostic centers, and research institutes. The global nuclear medicine/radiopharma

ceutical market is expected to grow with a CAGR of 9% from 2019 to 2024. The major drivers for this market are increasing incidence and prevalence of cancer and cardiovascular diseases (CVD) and growing investment through public private partnerships to modernize diagnostic imaging centers, alpha radioimmunotherapy (RIT) based targeted cancer treatment, and advances in radiotracers.

A report of more than 150-pages is developed to help in your business decisions. Sample figures with some insights are shown below. To learn the scope of, benefits, companies researched and other details of nuclear medicine/radiopharmaceuticals market report download the report brochure



Nuclear Medicine/Radiopharmaceutical Market by Segments

Nuclear Medicine/Radiopharmaceutical Market Trends and Forecast

Nuclear Medicine/Radiopharmaceutical Market Share
 


The study includes the nuclear medicine/radiopharmaceutical market size and forecast for the global nuclear medicine/radiopharmaceutical market through 2024, segmented by product type, application, end user, and region as follows:

By Product Type [$M shipment analysis for 2013 – 2024]:
  • Diagnostic Nuclear Medicine/Radiopharmaceutical
    • SPECT Radiopharmaceutical
    • PET Radiopharmaceutical
  • Therapeutic Nuclear Medicine/Radiopharmaceutical
    • Beta Emitters
    • Alpha Emitters
    • Brachytherapy

By Application [$M shipment analysis for 2013 – 2024]:
  • Cardiology
  • Lymphoma
  • Thyroid
  • Neurology
  • Oncology
  • Bone Metastasis
  • Endocrine Tumors

By End User [$M shipment analysis for 2013 – 2024]:
  • Hospitals and Diagnostic Centers
  • Research Institutes

By Region [$M shipment analysis for 2013 – 2024]:
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
  • Rest of the World (ROW)
    • Brazil

Some of the nuclear medicine/radiopharmaceutical companies profiled in this report include Cardinal Health, Mallinckrodt, GE Healthcare, Lantheus Medical Imaging, Bayer, Bracco Imaging, Eczacibasi-Monrol Nuclear Products, Noridian, and Iba Molecular.

Some of the features of "Global Nuclear Medicine/Radiopharmaceuticals Market 2019-2024: Trends, Forecast, and Opportunity Analysis" include
  • Market size estimates:Global nuclear medicine/radiopharmaceuticals market size estimation in terms of value ($M) shipment.
  • Trend and forecast analysis:Market trend (2013-2018) and forecast (2019-2024) by segments and region.
  • Segmentation analysis:Global market size by various applications such as by product type, application, end user, and region.
  • Regional analysis:Global nuclear medicine/radiopharmaceuticals market breakdown by North America, Europe, Asia Pacific, and the Rest of the World
  • Growth opportunities:Analysis on growth opportunities in different applications and regions for nuclear medicine/radiopharmaceuticals in the global nuclear medicine/radiopharmaceuticals market.
  • Strategic analysis:This includes M&A, new product development, and competitive landscape for nuclear medicine/radiopharmaceuticals in the global nuclear medicine/radiopharmaceuticals market.
  • Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising potential, high-growth opportunities for the global nuclear medicine/radiopharmaceutical market by product type (diagnostic nuclear medicine/radiopharmaceutical (SPECT radiopharmaceutical, PET radiopharmaceutical), and therapeutic nuclear medicine/radiopharmaceutical (beta emitters, alpha emitters and brachytherapy), application (Cardiology, lymphoma, thyroid, oncology, neurology, bone metastasis, endocrine tumors), end user (hospitals and diagnostic centers, and research institutes), and region (North America, Asia-Pacific, Europe, Rest of the World(ROW))?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which regions will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the drivers and challenges of the nuclear medicine/radiopharmaceutical market?
Q.5. What are the business risks and threats to the nuclear medicine/radiopharmaceutical market?
Q.6. What are emerging trends in this nuclear medicine/radiopharmaceutical market and the reasons behind them?
Q.7. What are some changing demands of customers in the nuclear medicine/radiopharmaceutical market?
Q.8. What are the new developments in the nuclear medicine/radiopharmaceutical market? Which companies are leading these developments?
Q.9. Who are the major players in this nuclear medicine/radiopharmaceutical market? What strategic initiatives are being implemented by key players for business growth?
Q.10. What are some of the competitive products and processes in this nuclear medicine/radiopharmaceutical area and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11. What M&A activities have taken place in the last 5 years in this nuclear medicine/radiopharmaceutical market?
Table of Contents

1. Executive Summary

2. Market Background and Classifications
   2.1: Introduction, Background, and Classifications
   2.2: Supply Chain
   2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2013 to 2024
   3.1: Macroeconomic Trends and Forecast
   3.2: Global Nuclear Medicine/Radiopharmaceuticals Market: Trends and Forecast
   3.3: Global Nuclear Medicine/Radiopharmaceuticals Market by Product Type
   3.3.1: Diagnostic Nuclear Medicine / Radiopharmaceutical
   3.3.1.1: SPECT Radiopharmaceutical
   3.3.1.2: PET Radiopharmaceutical
   3.3.2: Therapeutic Nuclear Medicine/Radiopharmaceutical
   3.3.2.1: Beta Emitters
   3.3.2.2: Alpha Emitters
   3.3.2.3: Brachytherapy
   3.4: Global Nuclear Medicine/Radiopharmaceuticals Market by Application
   3.4.1: Cardiology
   3.4.2: Lymphoma
   3.4.3: Thyroid
   3.4.4: Neurology
   3.4.5: Oncology
   3.4.6: Bone Metastasis
   3.4.7: Endocrine Tumors
   3.5: Global Nuclear Medicine/Radiopharmaceuticals Market by End Use Industry
   3.5.1: Hospitals and Diagnostic Centers
   3.5.2: Research Institutes

4. Market Trends and Forecast Analysis by Region
   4.1: Global Nuclear Medicine/Radiopharmaceuticals Market by Region
   4.2: North American Nuclear Medicine/Radiopharmaceuticals Market
   4.2.1: Market by End Use Industry: Hospitals and Diagnostic Centers, and Research Institutes
   4.3: European Nuclear Medicine/Radiopharmaceuticals Market
   4.3.1: Market by End Use Industry: Hospitals and Diagnostic Centers, and Research Institutes
   4.4: APAC Nuclear Medicine/Radiopharmaceuticals Market
   4.4.1: Hospitals and Diagnostic Centers, and Research Institutes
   4.5: ROW Nuclear Medicine/Radiopharmaceuticals Market  
   4.5.1: Hospitals and Diagnostic Centers, and Research Institutes

5. Competitor Analysis
   5.1: Product Portfolio Analysis
   5.2: Market Share Analysis
   5.3: Operational Integration
   5.4: Geographical Reach
   5.5: Porter’s Five Forces Analysis

6. Growth Opportunities and Strategic Analysis
   6.1: Growth Opportunity Analysis
   6.1.1: Growth Opportunities for Global Nuclear Medicine/Radiopharmaceuticals Market by
              Product Type
   6.1.2: Growth Opportunities for Global Market by Application
   6.1.3: Growth Opportunities for Global Nuclear Medicine/Radiopharmaceuticals Market by
             End Use Industry
   6.1.4: Growth Opportunities for Global Nuclear Medicine/Radiopharmaceuticals Market by Region
   6.2: Emerging Trends in Global Nuclear Medicine/Radiopharmaceuticals Market
   6.3: Strategic Analysis
   6.3.1: New Product Development
   6.3.2: Capacity Expansion of Global Nuclear Medicine/Radiopharmaceuticals Market
   6.3.3: Mergers, Acquisitions and Joint Ventures in the Global Market

7. Company Profiles of Leading Players
   7.1: Cardinal Health
   7.2: Mallinckrodt
   7.3: GE Healthcare
   7.4: Lantheus Medical Imaging
   7.5: Bayer
   7.6: Bracco Imaging
   7.7: Eczacibasi-Monrol Nuclear Products
   7.8: Noridion
   7.9: IBA Molecular
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Nuclear Medicine/Radiopharmaceutical Market: Trends, Opportunities and Competitive Analysis Full Report $ 4,850
142 figures/charts and 107 tables are provided in this 150 - page report
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data 
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
 
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process. 
 

Please sign in below to get report brochure - Nuclear Medicine/Radiopharmaceutical Market.

At Lucintel, we respect your privacy and maintain the confidentiality of information / data provided by you
(Please enter your corporate email. * These fields are mandatory )
Have an Account / Returning Visitors?

Follow us on